Current therapy of the failing heart.

Myocardial dysfunction eventuating in systolic and diastolic pump function abnormalities is a consequence of a wide variety of cardiac diseases. The symptoms that develop in this syndrome appear to be related as much to peripheral and neurohormonal mechanisms as to the underlying pathological and cardiac functional abnormality. Relief of symptoms, slowing of the progression of the cardiac functional abnormality, and prolongation of life provide the major agenda for the physician faced with the management of these patients. Judicious use of vasodilators, diuretics, digoxin, dietary therapy, and exercise therapy can relieve symptoms and improve the quality of life in most patients suffering from this syndrome. Recent evidence that vasodilator drugs can prolong life now provides the physician with further justification for routine use of this class of compounds. The eventual solution to the high mortality in this common disease process may be prevention of the development of overt heart failure by more prompt recognition and early treatment of the signs of ventricular dysfunction. This possibility must await the completion of current and proposed clinical trials.

[1]  E. Sonnenblick,et al.  Sustained Hemodynamic and Clinical Effects of a New Cardiotonic Agent, WIN 47203, in Patients with Severe Congestive Heart Failure , 1983, Circulation.

[2]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[3]  J. Cohn,et al.  New inotropic drugs for heart failure. , 1987, JAMA.

[4]  J. Cohn,et al.  Comparative Hemodynamic Effects of Inotropic and Vasodilator Drugs in Severe Heart Failure , 1977, Circulation.

[5]  R. A. Johnson,et al.  Heart failure in outpatients: a randomized trial of digoxin versus placebo. , 1982, The New England journal of medicine.

[6]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[7]  J. Cohn,et al.  Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure. , 1980, The American journal of cardiology.

[8]  M. Wilén,et al.  Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. , 1984, Circulation.

[9]  J. Cohn,et al.  Acute and Long‐term Response to an Oral Converting‐enzyme Inhibitor, Captopril, in Congestive Heart Failure , 1980, Circulation.

[10]  T. Rector Patients' self-assessment of their congestive heart failure : Content, reliability, and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire , 1987 .

[11]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[12]  F. Tristani,et al.  Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. , 1987, Circulation.

[13]  J. Cohn,et al.  Role of the Renin-Angiotensin System in the Systemic Vasoconstriction of Chronic Congestive Heart Failure , 1978, Circulation.

[14]  A. Moss,et al.  Digitalis‐associated Cardiac Mortality After Myocardial Infarction , 1981, Circulation.

[15]  J. Cohn,et al.  Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. , 1978, Chest.

[16]  P. Poole‐Wilson,et al.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. , 1987, British heart journal.

[17]  D. Roden,et al.  Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. , 1986, The American journal of cardiology.

[18]  J. Cohn,et al.  Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. , 1980, The American journal of medicine.

[19]  J. Cohn,et al.  Treatment of refractory heart failure with infusion of nitroprusside. , 1974, The New England journal of medicine.

[20]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[21]  J. Parker,et al.  Tolerance to isosorbide dinitrate: rate of development and reversal. , 1983, Circulation.

[22]  J. Cohn,et al.  Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. , 1987, American heart journal.

[23]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[24]  A J LINZBACH,et al.  Heart failure from the point of view of quantitative anatomy. , 1960, The American journal of cardiology.

[25]  J. Cohn,et al.  Hyponatraemia as a marker for high renin heart failure. , 1982, British heart journal.

[26]  J. Cohn Indications for digitalis therapy. A new look. , 1974, JAMA.

[27]  K. Wasserman,et al.  Determinants and detection of anaerobic threshold and consequences of exercise above it. , 1987, Circulation.

[28]  P. Bower Vasodilator therapy in congestive heart failure. , 1982, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society.

[29]  T. Levine,et al.  Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. , 1981, The American journal of cardiology.

[30]  J. Cohn,et al.  Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. , 1984, Circulation.

[31]  J. Cohn,et al.  Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure. , 1986, Circulation.

[32]  T. Levine,et al.  Acute Hemodynamic Effects of Nitrendipine in Chronic Congestive Heart Failure , 1984, Journal of cardiovascular pharmacology.